Covered recipient · General Payments record
NADISHANI T DISSANAYAKA
Allopathic & Osteopathic Physicians Internal Medicine Rheumatology
General Payments · PY2019–2024
$2,159.43
- Reported across 105 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $901.33 | 33 |
| Education | $158.99 | 2 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $344.39 | 10 |
| Amgen Inc. | $338.03 | 9 |
| Janssen Biotech, Inc. | $254.11 | 9 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $40.95 | 2 |
| GlaxoSmithKline, LLC. | $27.63 | 2 |
| Lilly USA, LLC | $20.29 | 1 |
| E.R. Squibb & Sons, L.L.C. | $19.18 | 1 |
| Acerta Pharma LLC | $15.74 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (35)
Sorted by paying entity, then date · as published by CMS
Program year 2024 20192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $9.25 | 02/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103645234 | CMS |
| ABBVIE INC. | $124.72 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103645236 | CMS |
| ABBVIE INC. | $15.12 | 03/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103645238 | CMS |
| ABBVIE INC. | $13.49 | 03/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103645240 | CMS |
| ABBVIE INC. | $11.80 | 03/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103645242 | CMS |
| ABBVIE INC. | $13.08 | 08/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103645244 | CMS |
| ABBVIE INC. | $11.75 | 10/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103645246 | CMS |
| ABBVIE INC. | $20.54 | 10/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103645248 | CMS |
| ABBVIE INC. | $12.19 | 11/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103645250 | CMS |
| ABBVIE INC. | $112.45 | 11/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103645252 | CMS |
| Amgen Inc. | $7.00 | 05/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115577845 | CMS |
| Amgen Inc. | $16.04 | 05/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115577853 | CMS |
| Amgen Inc. | $121.41 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115577889 | CMS |
| Amgen Inc. | $15.32 | 07/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115577862 | CMS |
| Amgen Inc. | $6.33 | 08/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115577897 | CMS |
| Amgen Inc. | $16.74 | 11/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115577874 | CMS |
| Amgen Inc. | $124.99 | 11/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117542478 | CMS |
| Amgen Inc. | $15.22 | 12/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115577881 | CMS |
| Amgen Inc. | $14.98 | 12/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115577905 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.74 | 02/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104742507 | CMS |
| E.R. Squibb & Sons, L.L.C. | $19.18 | 12/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101198392 | CMS |
| GlaxoSmithKline, LLC. | $14.31 | 01/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116440475 | CMS |
| GlaxoSmithKline, LLC. | $13.32 | 08/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116503615 | CMS |
| Janssen Biotech, Inc. | $16.58 | 05/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078377812 | CMS |
| Janssen Biotech, Inc. | $16.11 | 06/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078377669 | CMS |
| Janssen Biotech, Inc. | $59.99 | 06/26/2024 | Education | Undisputed | 01/23/2026 | 1078377600 | CMS |
| Janssen Biotech, Inc. | $16.58 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078377576 | CMS |
| Janssen Biotech, Inc. | $17.76 | 11/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078377665 | CMS |
| Janssen Biotech, Inc. | $9.56 | 11/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078377751 | CMS |
| Janssen Biotech, Inc. | $0.53 | 11/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078377783 | CMS |
| Janssen Biotech, Inc. | $99.00 | 12/13/2024 | Education | Undisputed | 01/23/2026 | 1078377517 | CMS |
| Janssen Biotech, Inc. | $18.00 | 12/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078377580 | CMS |
| Lilly USA, LLC | $20.29 | 08/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135230271 | CMS |
| Novartis Pharmaceuticals Corporation | $21.18 | 09/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086952839 | CMS |
| Novartis Pharmaceuticals Corporation | $19.77 | 10/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086952849 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.